Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type (2 selected)

Type

Guidance programme

Showing 51 to 100 of 2050

Published guidance, NICE advice and quality standards
TitleReference numberPublishedLast updated
Air pollution: outdoor air quality and healthNG70
Air pollution: outdoor air quality and healthQS181
Alcohol interventions in secondary and further educationNG135
Alcohol-use disorders: diagnosis and managementQS11
Alcohol-use disorders: diagnosis and management of physical complicationsCG100
Alcohol-use disorders: diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependenceCG115
Alcohol-use disorders: preventionPH24
Alcohol: preventing harmful use in the communityQS83
Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal)TA438
Alectinib for untreated ALK-positive advanced non-small-cell lung cancerTA536
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosisTA312
Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemiaTA393
Alitretinoin for the treatment of severe chronic hand eczemaTA177
Allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitusIPG257
Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancerTA816
Alpha-Stim AID for anxiety disordersMTG56
Alteplase for treating acute ischaemic strokeTA264
Amantadine, oseltamivir and zanamivir for the treatment of influenzaTA168
Ambu aScope4 Broncho for use in unexpected difficult airwaysMTG14
Ambulight PDT for the treatment of non-melanoma skin cancerMTG6
Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapyTA850
Anakinra for treating Still's diseaseTA685
AnaphylaxisQS119
Anaphylaxis: assessment and referral after emergency treatmentCG134
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxabanTA697
Angioplasty and stenting to treat peripheral arterial disease causing refractory erectile dysfunctionIPG546
Angiotensin II for treating vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal)TA859
Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal)TA793
Antenatal and postnatal mental healthQS115
Antenatal and postnatal mental health: clinical management and service guidanceCG192
Antenatal careNG201
Antenatal careQS22
Antimicrobial stewardshipQS121
Antimicrobial stewardship: changing risk-related behaviours in the general populationNG63
Antimicrobial stewardship: systems and processes for effective antimicrobial medicine useNG15
Antisocial behaviour and conduct disorders in children and young peopleQS59
Antisocial behaviour and conduct disorders in children and young people: recognition and managementCG158
Antisocial personality disorder: prevention and managementCG77
Anxiety disordersQS53
Aortic remodelling hybrid stent insertion during surgical repair of an acute type A aortic dissectionIPG733
Aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve diseaseIPG769
Aortic valve reconstruction with processed bovine pericardiumIPG604
Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancerTA740
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancerTA741
Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillationTA275
Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adultsTA245
Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolismTA341
AposHealth for knee osteoarthritisMTG76
Apremilast for treating active psoriatic arthritisTA433
Apremilast for treating moderate to severe plaque psoriasisTA419

Results per page

  1. 10
  2. 25
  3. 50
  4. All